These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer. Kawaguchi Y; Kopetz S; Kwong L; Xiao L; Morris JS; Tran Cao HS; Tzeng CD; Chun YS; Lee JE; Vauthey JN J Am Coll Surg; 2021 Aug; 233(2):272-284.e13. PubMed ID: 34111531 [TBL] [Abstract][Full Text] [Related]
9. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Brouquet A; Overman MJ; Kopetz S; Maru DM; Loyer EM; Andreou A; Cooper A; Curley SA; Garrett CR; Abdalla EK; Vauthey JN Cancer; 2011 Oct; 117(19):4484-92. PubMed ID: 21446046 [TBL] [Abstract][Full Text] [Related]
10. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation. Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911 [TBL] [Abstract][Full Text] [Related]
11. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. Pietrantonio F; Di Bartolomeo M; Cotsoglou C; Mennitto A; Berenato R; Morano F; Coppa J; Perrone F; Iacovelli R; Milione M; Alessi A; Vaiani M; Bossi I; Ricchini F; Scotti M; Caporale M; Bajetta E; de Braud F; Mazzaferro V Clin Colorectal Cancer; 2017 Sep; 16(3):e191-e198. PubMed ID: 27979717 [TBL] [Abstract][Full Text] [Related]
12. RAS/TP53 Co-mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease. Lillemoe HA; Passot G; Kawaguchi Y; DeBellis M; Glehen O; Chun YS; Tzeng CD; Aloia TA; Lopez J; Vauthey JN Ann Surg; 2022 Aug; 276(2):357-362. PubMed ID: 33351476 [TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173 [TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301 [TBL] [Abstract][Full Text] [Related]
15. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M; Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731 [TBL] [Abstract][Full Text] [Related]
16. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870 [TBL] [Abstract][Full Text] [Related]